KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Operating Leases (2019 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Operating Leases for 7 consecutive years, with $41.0 million as the latest value for Q4 2025.

  • Quarterly Operating Leases rose 49.65% to $41.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $41.0 million through Dec 2025, up 49.65% year-over-year, with the annual reading at $41.0 million for FY2025, 49.65% up from the prior year.
  • Operating Leases for Q4 2025 was $41.0 million at Supernus Pharmaceuticals, down from $42.2 million in the prior quarter.
  • The five-year high for Operating Leases was $47.8 million in Q4 2021, with the low at $24.4 million in Q2 2025.
  • Average Operating Leases over 5 years is $37.5 million, with a median of $40.4 million recorded in 2022.
  • Peak annual rise in Operating Leases hit 49.65% in 2025, while the deepest fall reached 37.41% in 2025.
  • Over 5 years, Operating Leases stood at $47.8 million in 2021, then dropped by 10.44% to $42.8 million in 2022, then fell by 22.42% to $33.2 million in 2023, then fell by 17.51% to $27.4 million in 2024, then surged by 49.65% to $41.0 million in 2025.
  • According to Business Quant data, Operating Leases over the past three periods came in at $41.0 million, $42.2 million, and $24.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.